Kura Oncology (KURA) Earnings Date & Reports

Key Takeaways

• Analysts, on average, expect Kura Oncology to report a net loss of roughly $0.81 to $0.83 per share for the third quarter of 2026, with revenue estimates clustered between approximately $22 million and $25 million.
• Top-line growth will hinge on commercial uptake of KOMZIFTI (ziftomenib), the company's FDA-approved menin inhibitor for NPM1-mutated acute myeloid leukemia (AML).
• Kura beat consensus on both earnings per share (EPS) and revenue in the second quarter of 2026, but revenue came in below expectations in the first quarter of 2026.
• Investors will closely watch collaboration revenue from the Kyowa Kirin partnership and the company's cash runway, which stood at about $519 million at the end of the prior quarter.
• Pipeline milestones, including enrollment in the KOMET-017 Phase 3 trials and upcoming data readouts, are key drivers of the investment narrative heading into the report.
• For additional context on the company's developments, explore Major News, Today's Price Move, Price Targets, and Forecast.
• Discover AI-driven trading strategies by exploring Trending AI Robots.

Earnings Context and Why It Matters

Kura Oncology's third-quarter 2026 report marks another checkpoint in the company's transition from a clinical-stage developer into an early commercial-stage precision oncology business. The quarter will be judged largely on the trajectory of KOMZIFTI, which generated roughly $9.1 million in net product revenue during its first full quarter following FDA approval. Because Kura remains unprofitable while it funds launch and research and development (R&D) efforts, investors are watching both revenue momentum and cash burn. The company ended the second quarter with about $519 million in cash, a buffer management says supports operations well into the future. Against this backdrop, the earnings release offers a timely read on demand, expense control, and execution across a pipeline aimed at genetically defined cancers.

Earnings Expectations

Consensus forecasts point to a net loss of approximately $0.81 to $0.83 per share for the third quarter of 2026, compared with a loss of $0.85 per share in the year-ago period. Revenue estimates range from about $22 million to $25 million, up from roughly $20.75 million reported a year earlier. These figures blend KOMZIFTI product sales with collaboration revenue tied to Kura's global partnership with Kyowa Kirin.

Kura enters the quarter with a mixed track record. In the second quarter of 2026, the company posted a loss of $0.77 per share, beating the consensus estimate of a $0.88 loss, while revenue of $20.87 million topped the expected $20.16 million. However, first-quarter 2026 revenue of about $18.3 million fell short of analyst projections. Given that Kura has beaten EPS estimates in roughly three of its last seven quarters, the key uncertainty is whether launch momentum and collaboration income can outpace rising operating expenses as the company scales its commercial organization and expands clinical trial activity.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters, including industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Kura Oncology ahead of key catalysts, the AI Screener offers a structured way to identify and compare potential opportunities across sectors.

Market Reaction and Investor Sentiment

Sentiment heading into the report reflects a stock that has traded within a wide range over the past year while the market weighs early commercial traction against ongoing losses. Analyst coverage remains broadly positive, with the majority of ratings at Buy or equivalent and consensus price targets well above the stock's recent trading levels. Still, the share price has lagged those targets, suggesting investors are waiting for clearer evidence that the KOMZIFTI launch can scale and that expenses are being managed. Key risk factors around this earnings event include the pace of new patient starts, the durability of collaboration revenue, and any commentary on cash runway or future financing needs. A meaningful deviation in launch metrics or guidance could drive outsized post-earnings volatility.

Forward Outlook and Key Factors to Monitor

Looking beyond the print, investors will focus on the sustainability of KOMZIFTI's commercial ramp. Early signals have shown steady growth in patient starts and market share in newly diagnosed NPM1-mutant AML, but the launch is still in its early quarters. Sustained revenue growth will depend on continued physician adoption, payer access, and expansion into additional treatment settings.

Pipeline progress remains a central catalyst. Kura has emphasized rapid enrollment in its KOMET-017 Phase 3 frontline trials, with top-line results not expected until later in the decade. Nearer term, the company has guided toward additional combination data readouts across 2026 and 2027. Investors will also monitor spending trends, as higher R&D and selling, general, and administrative costs have widened losses as the commercial organization scales.

Cash runway and the collaboration with Kyowa Kirin are additional areas of focus. Management has signaled that current resources should fund operations into 2028, supported by anticipated collaboration funding and milestone payments. Any update to that outlook, or to milestone timing, could shift the market's view of the company's financial flexibility as it advances multiple clinical programs.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations